Daniel Margolis
Partner
New York
Daniel Margolis
Partner
New York
Contact Details
Dan is a partner in the Intellectual Property practice. Clients rely upon the combination of legal and scientific expertise he brings to his practice, which focuses on patent litigation and strategic counselling, with a particular emphasis on pharmaceuticals and chemical technologies. His expertise allows him to address complex issues for his clients with respect to legal and overall business strategies.
Qualifications
Professional
Admitted to the Bar of the State of New York
U.S. District Court for the Southern District of New York
U.S. District Court for the Northern District of New York
Academic
J.D., New York University School of Law, 2006
Ph.D., Chemical Engineering, Carnegie Mellon University, 2003
B.S., Chemical Engineering, Rutgers University, 1998
Related articles
News: 25 February 2022
A&O today announced that Elizabeth Holland, Bill James, John Bennett, Nick Mitrokostas and Daniel Margolis will join as partners in A&O’s U.S. Intellectual Property (IP) Litigation practice, focused…
Experience highlights
Fresenius representation in the overall strategy and patent protection related to its application to market a biosimilar. We have filed seven IPRs at the PTAB, six of which have been instituted.
Novartis in ITC and District Court patent litigation adverse to Regeneron on the Eylea® Pre-filled Syringe. We are also counselling Novartis in connection with defending the validity of its U.S. Patent No. 9,220,631(pre-filled syringe drug product patent) before the PTAB.
Qualifications
Professional
Admitted to the Bar of the State of New York
U.S. District Court for the Southern District of New York
U.S. District Court for the Northern District of New York
Academic
J.D., New York University School of Law, 2006
Ph.D., Chemical Engineering, Carnegie Mellon University, 2003
B.S., Chemical Engineering, Rutgers University, 1998
Other noteworthy experience
Advising:
- Teva representation in a patent infringement litigation against multiple generic defendants involving patents directed to a process for manufacturing glatiramer acetate (Copaxone®). [In re: Copaxone 775 Patent Litigation (D. Del.)]
- Teva Pharmaceuticals and Yeda Research and Development representation in the trial of consolidated cases in the District of Delaware relating to Teva’s 40mg three times weekly Copaxone product.
- Enzymotec representation in a United States International Trade Commission investigation concerning alleged infringement by Enzymotec’s krill oil supplements. The representation also involved an inter partes review before the Patent Trial and Appeal Board in the United States Patent and Trademark Office. [In the Matter of Certain Omega-3 Extracts from Marine or Aquatic Biomass and Products Containing the Same (ITC).]*
- Globally Diversified Conglomerate conducting IP due diligence regarding freedom to operate and scope and strength of patent protection.
- Biotechnology Company provided freedom to operate analysis.
*Experience prior to joining Allen & Overy.
